AIM: To investigate the effect of macular focal/grid laser photocoagulation with Ranibizumab on the treatment of diabetic macular edema(DME).

METHODS: Totally 70 patients(99 eyes)with DME treated in our hospital from August 2014 to August 2016 were randomly divided into the observation group and the control group, with 50 eyes and 49 eyes, respectively. Patients in control group were treated with macular focal/grid laser photocoagulation, and based on this, the observation group was treated with intravitreal injection of ranibizuma at 5-7d before operation. The best corrected visual acuity(BCVA)before and after operation was compared between the two groups. Central macular thickness(CMT)was examined by optical coherence tomography(OCT), and fluorescein fundus angiography(FFA)was used to examine the leakage area of retinal neovascularization(RNV)and macular edema.

RESULTS: The BCVA in both groups increased significantly after operation, and the BCVA in observation group was significantly higher than that of the control group at each time point after operation, the difference was statistically significant(P<0.05). After treatment, the CMT and leakage area of RNV in both groups significantly decreased, and the leakage area of the observation group were significantly less than those in control group at each time point(P<0.05). There were different degrees of macular edema leakage in the two groups before operation, and the proportion of eye with macular edema and leakage in observation group was significantly lower than that in control group, the difference was statistically significant(P<0.05). No obvious complications occurred in the two groups.

CONCLUSION: Compared with macular focal/grid laser photocoagulation, the combination of macular focal/grid laser photocoagulation and ranibizumab has better curative effect on DME and RNV reduction. Moreover, the patients' visual acuity improve significantly with a higher safety.